Zhou J - Search Results

1

Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.

Lu J, Yu K, Fan S, Liu W, Dong Z, Li J, Wang X, Hai X, Zhou J. Lu J, et al. Among authors: zhou j. Toxicol Appl Pharmacol. 2019 Sep 15;379:114687. doi: 10.1016/j.taap.2019.114687. Epub 2019 Jul 19. Toxicol Appl Pharmacol. 2019. PMID: 31330140

2

HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells.

Guo M, Wang W, Hai X, Zhou J. Guo M, et al. Among authors: zhou j. J Pharm Biomed Anal. 2017 Oct 25;145:356-363. doi: 10.1016/j.jpba.2017.07.001. Epub 2017 Jul 6. J Pharm Biomed Anal. 2017. PMID: 28711674

3

Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.

Gao C, Hu S, Guo M, Hai X, Zhou J. Gao C, et al. Among authors: zhou j. Cancer Chemother Pharmacol. 2018 Aug;82(2):229-236. doi: 10.1007/s00280-018-3606-8. Epub 2018 May 29. Cancer Chemother Pharmacol. 2018. PMID: 29845392 Clinical Trial.

4

AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.

Lu J, Hu S, Wang W, Li J, Dong Z, Zhou J, Hai X. Lu J, et al. Among authors: zhou j. Toxicol Sci. 2018 Nov 1;166(1):219-227. doi: 10.1093/toxsci/kfy210. Toxicol Sci. 2018. PMID: 30376134

5

Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury.

Gao C, Fan S, Hostetter TH, Wang W, Li J, Guo M, Zhou J, Hai X. Gao C, et al. Among authors: zhou j. Br J Clin Pharmacol. 2019 Apr;85(4):849-853. doi: 10.1111/bcp.13875. Epub 2019 Feb 14. Br J Clin Pharmacol. 2019. PMID: 30677159 Free PMC article.

6

Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.

Guo M, Wang B, Liu S, Wang W, Gao C, Hu S, Fan S, Hai X, Zhou J. Guo M, et al. Among authors: zhou j. Expert Rev Clin Pharmacol. 2019 Apr;12(4):371-378. doi: 10.1080/17512433.2019.1586532. Epub 2019 Mar 11. Expert Rev Clin Pharmacol. 2019. PMID: 30795697

7

Speciation analysis of arsenic in urine samples from APL patients treated with single agent As₂O₃ by HPLC-HG-AFS.

Guo M, Li J, Fan S, Liu W, Wang B, Gao C, Zhou J, Hai X. Guo M, et al. Among authors: zhou j. J Pharm Biomed Anal. 2019 Jul 15;171:212-217. doi: 10.1016/j.jpba.2019.04.014. Epub 2019 Apr 8. J Pharm Biomed Anal. 2019. PMID: 31009876

8

Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As₂O₃.

Liu WS, Wang XY, Lu J, Zhang YM, Ye XM, Li JM, Zhao QL, Wu ZQ, Zhou J, Hai X. Liu WS, et al. Among authors: zhou j. Arch Toxicol. 2020 Apr;94(4):1203-1213. doi: 10.1007/s00204-020-02686-6. Epub 2020 Feb 28. Arch Toxicol. 2020. PMID: 32112223

9

Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.

Guo M, Zhou J, Fan S, Li L, Chen H, Lin L, Zhao Q, Wang X, Liu W, Wu Z, Hai X. Guo M, et al. Among authors: zhou j. Expert Rev Clin Pharmacol. 2021 Apr;14(4):503-512. doi: 10.1080/17512433.2021.1893940. Epub 2021 Mar 8. Expert Rev Clin Pharmacol. 2021. PMID: 33678104

10

The effect of arsenic trioxide on QT interval prolongation during APL therapy.

Zhou J, Meng R, Li X, Lu C, Fan S, Yang B. Zhou J, et al. Chin Med J (Engl). 2003 Nov;116(11):1764-6. Chin Med J (Engl). 2003. PMID: 14642155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51,428 results

Search Page